Announced details
Redasemtide has already been out-licensed to Shionogi & Co.,Ltd. The applicants for the patent covering the cartilage disease indication are StemRIM Inc. and National University Corporation Osaka University.
Shionogi & Co.,Ltd.: Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功). Redasemtide has already been out-licensed by the Company to Shionogi & Co.,Ltd. National University Corporation Osaka University: co-applicant for the patent. Other details: Not disclosed.
Application number: 2019367943. Registration (publication) number: To be determined. Validity period: Not disclosed.
There will be no impact on full-year business performance for the fiscal year ending July 2026. If any matter requiring disclosure arises, it will be disclosed promptly.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine Redasemtide (HMGB1 fragment peptide), S-005151 |
| Counterparty | Shionogi & Co.,Ltd., Osaka University National University Corporation |
| Counterparty overview | Shionogi & Co.,Ltd.: Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功). Redasemtide has already been out-licensed by the Company to Shionogi & Co.,Ltd. National University Corporation Osaka University: co-applicant for the patent. Other details: Not disclosed. |
| Relationship with the Company | Redasemtide has already been out-licensed to Shionogi & Co.,Ltd. The applicants for the patent covering the cartilage disease indication are StemRIM Inc. and National University Corporation Osaka University. |
| Applicable area | Traumatic cartilage defects of the joints, Osteoarthritis, Osteochondritis dissecans |
| Registration number and expiry date | Application number: 2019367943. Registration (publication) number: To be determined. Validity period: Not disclosed. |
| Impact on Business Performance | There will be no impact on full-year business performance for the fiscal year ending July 2026. If any matter requiring disclosure arises, it will be disclosed promptly. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the indications for Redasemtide and secure the potential to develop treatments for cartilage diseases in Australia.